Jump to content
Sclero Forums

Search the Community

Showing results for tags 'clinical trials'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 37 results

  1. Would you like to help scientists find a cure for scleroderma? Dozens of clinical trials for scleroderma and pulmonary hypertension are actively recruiting now. Review them and be sure to ask your scleroderma expert about the ones you are interested in. Posted 12/09/2014. (Also see: Current Clinical Trials and Scleroderma Experts) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Should all digital ulcers (DUs) be included in future clinical trials of systemic sclerosis (SSc)–related digital vasculopathy? We would encourage the expert SSc community to reconsider the rationale for including only fingertip DUs in future SSc clinical trials, and suggest an agenda for future research. PubMed, Med Hypotheses, 2018 Jul;116:101-104. (Also see Research on Digital Ulcers) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis (SSc). The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. PubMed, Ann rheumatologist Dis, 05/31/2018. (Also see Interleukins and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Lenabasum Safe and Effective in Diffuse Scleroderma Patients, One–year Trial Data Show. Lenabasum, by Corbus Pharmaceuticals, was shown to be safe, well-tolerated and of benefit to patients treated for one year in a long-term extension of a Phase 2 trial. Scleroderma News, 05/17/2018. (Also see Clinical Trials and Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. iBio Selects Lead Candidate for its Fibrosis Therapeutics Program. iBio, Inc. announced today that it had selected an E4-Fc fusion protein as its lead candidate for further development of a drug against fibrotic diseases, including systemic sclerosis and idiopathic pulmonary fibrosis. Globe Newswire, 03/14/2018. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Corbus Wins Expanded U.S. Patent Coverage of Anabasum Therapy for Systemic Sclerosis. Corbus Pharmaceuticals has extended its intellectual property portfolio with a new patent for its investigative cannabinoid–derived drug candidate anabasum to treat inflammatory diseases. Scleroderma News, 11/02/2017. (Also see Clinical Trials and Endocannabinoid System) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double–Blind, Placebo–Controlled, Pilot Trial. Significant decrease in expression of B–cell signaling and pro–fibrotic genes and pathways was observed in patients with improved modified Rodnan skin score in the belimumab group but not in the placebo group. PubMed, Arthritis Rheumatol, 10/26/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Preclinical Study Shows IVA337’s Potential in Treating SSc Skin and Cardiovascular Complications. Inventiva’s lead therapy candidate IVA337 for the treatment of systemic sclerosis (SSc) was shown to prevent the progression of lung fibrosis and the remodeling of blood vessels in preclinical animal models of lung fibrosis and systemic sclerosis. Scleroderma News, 07/28/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. American Medical Association Adding Cytori’s Cell–Based Therapy for Scleroderma Hand Problems to Key Database. The American Medical Association is adding descriptions of Cytori Therapeutics’ cell–based therapy for scleroderma of the hands to its authoritative database of medical procedures, services and technology. Scleroderma News, 07/11/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Galectin’s Candidate Therapy GR-MD-02 Patent Extended to Cover Several Illnesses Including Systemic Sclerosis. The U.S. Patent and Trademark Office has granted Galectin Therapeutics a new patent that extends coverage of its candidate therapy GR-MD-02 to treat systemic sclerosis. Scleroderma News, 06/27/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis. Genentech has completed enrollment for a Phase III clinical trial investigating the use of Actemra (tocilizumab) in patients with systemic sclerosis. The aim of the study is to assess the efficacy and safety of Actemra compared to placebo for the treatment of systemic sclerosis. ClinicalTrials.gov, 07/25/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Efficacy of mycophenolate mofetil (MMF) and oral cyclophosphamide (CYC) on skin thickness: Post–hoc analyses from the Scleroderma Lung Study I and II. (SLS-I and II) In SLS-II, MMF and CYC resulted in improvements in the modified Rodnan skin score in diffuse cutaneous systemic sclerosis over 24 months. PubMed, Arthritis Care Res (Hoboken), 05/23/2017. (Also see Clinical Trials and Immunosuppressants) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Fibrocell’s FX-013 Therapy Wins FDA Rare Pediatric Disease Designation for Localized Scleroderma. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to FX-013, a Fibrocell gene therapy candidate to treat children with moderate to severe localized scleroderma. Scleroderma News, 06/13/2017. (Also see Clinical Trials and Juvenile Scleroderma Research) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  14. CATALYST – for patients with CTD-PAH. CATALYST is a Phase III clinical study evaluating the safety and efficacy of bardoxolone methyl (an oral medication) for the treatment of pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH). Approximately 200 patients will be enrolled at centres in various countries around the world. Reata Pharmaceuticals, Inc., 06/29/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  15. Cytori Logs Final 48 Week Patient Follow Up Visit in Scleroderma Trial. Cytori Therapeutics, Inc. today announced that it has now completed all 48 week follow up monitoring visits in its U.S. FDA approved Phase III STAR trial. A total of 88 subjects were enrolled and the last subject’s 48 week visit was conducted earlier this week. Globe Newswire, 05/23/2017. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  16. Joelf

    Expanded Access Programs.

    Expanded Access Programs. A Expanded Access Program (EAP) allows physicians and patients access to much needed medicines when there are no other viable options left. These may be investigational therapies as well as drugs not available in the patients' country and the ultimate intention is to treat unmet clinical need. WEP Clinical. (Also see Clinical Trials and Medication Programs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  17. Corbus to Present Promising Data on Resunab as Systemic Sclerosis Treatment. Corbus Pharmaceuticals will present results showing that Resunab (JBT-101) can trigger specific molecular pathways which resolve inflammation and halt fibrosis. Scleroderma News, 03/07/2017. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  18. Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum (HICS) in systemic sclerosis. Our results suggest mechanisms of action for HICS, including upregulation of α-MSH, that has been shown to be anti–fibrotic in preclinical models, and possible markers to be included in future trials targeting skin in diffuse cutaneous systemic sclerosis. PubMed, Arthritis Res Ther, 2017 Mar 7;19(1):45. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  19. Improved cough and cougho–specific quality of life in patients treated for sclerodermao–related interstitial lung disease (SSc–ILD): Results of Scleroderma Lung Study II. Frequent cough occurs commonly in SSc–ILD and might serve as a useful surrogate marker of treatment response in SSc–ILD trials. PubMed, Chest, 12/22/2016. (Also see Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  20. Systemic sclerosis : What is currently available for treatment? Therapy options in systemic sclerosis have changed over the past 10 years and this trend will also continue in the future. PubMed, Internist (Berl), 2016 Dec;57(12):1155-1163. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  21. Cytori Presents Scleroderma Clinical Trial Data at the 2016 American College of Rheumatology Annual Meeting. Cytori Therapeutics, Inc. present data from its STAR Phase 3 clinical trial describing progress, preliminary blinded patient characteristics, and safety of adipose–derived regenerative cells (ADRCs) for treatment of scleroderma hand dysfunction at the Annual Meeting of the American College of Rheumatology on November 15, 2016. Business Wire, 10/26/2016. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  22. Resunab, Potential Scleroderma Treatment, Shows Ability to Stop Inflammation in Early Clinical Trial. Corbus Pharmaceuticals reported new findings supporting the anti–inflammatory actions of its lead compound Resunab (JBT-101), which is currently being explored in a clinical trial for scleroderma. Scleroderma News, 09/29/2016. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  23. Nintedanib receives orphan drug designation for systemic sclerosis. The FDA has granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of (SSc), including associated interstitial lung disease (SSc–ILD). Pharmacy Times, 09/27/2016. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  24. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. More conclusive evaluation is needed; however, buspirone could potentially be given under observation for objective improvement in all patients with SSc who report reflux symptoms despite undergoing standard treatment. BioMed Central, Arthritis Research & Therapy, 09/01/2016. (Also see Dysmotility Syndrome in Systemic Scleroderma and Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  25. The protective effect of hydrogen sulfide (H2S) on systemic sclerosis associated skin and lung fibrosis in mice model. We demonstrate the beneficial effects of H2S on SSc–associated skin and lung fibrosis. H2S may be a potential therapy against this intractable disease. PubMed, Springerplus, 2016 Jul 15;5(1):1084. (Also see Scleroderma Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×